第30天SUVmax预测接受CAR-T细胞治疗后达到部分缓解/疾病稳定的淋巴瘤患者的进展
该回顾性研究纳入2018年1月至2021年2月在MD Anderson癌症中心接受阿基仑赛注射液(axi-cel)治疗的LBCL患者,分析第30天PET-CT显示部分缓解(PR)或疾病稳定(SD)患者的后续转归。50例D30 PR/SD患者中13例(26%)转为完全缓解(CR),95例D30 CR患者中72例(76%)维持CR;单因素分析显示D30 SUVmax较低与PR/SD转为CR相关(P < .001),所有D30 SUVmax ≥ 10的患者均进展。
要点
- D30 PET-CT显示PR/SD的LBCL患者中约70%会发生进展。
- D30 SUVmax ≥ 10的患者全部出现进展。
- D30 PR/SD转为CR者与D30起持续CR者的中位PFS无显著差异(P = .19)。
核心结论
- D30 SUVmax是预测接受axi-cel治疗的LBCL患者从D30 PR/SD转为后续CR的唯一D30相关因素(P < .001),所有D30 SUVmax ≥ 10的患者均进展。
- 需要基于组织活检和无创诊断检测的新型预测和预后标志物来更有效地识别这些患者并表征其残留疾病的生物学特征。
研究设计与样本
- 回顾性研究,纳入2018年1月至2021年2月在MD Anderson癌症中心接受axi-cel治疗的LBCL患者。
- 分析人群包括50例D30 PET-CT显示PR/SD的患者和95例D30显示CR的患者。
主要发现
- 50例D30 PR/SD患者中,13例(26%)转为CR;95例D30 CR患者中,72例(76%)维持CR。
- 单因素分析中,唯一与D30 PR/SD转为后续CR相关的D30前第5天特征是较高的血小板计数(P = .05)。
- 单因素分析中,唯一与D30 PR/SD转为后续CR相关的D30因素是较低的SUVmax(P < .001);所有D30 SUVmax ≥ 10的患者均进展。
- 中位随访12个月后,从D30 PR/SD转为后续CR的患者与自D30起持续CR的患者之间,中位无进展生存期无显著差异(P = .19)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
About 70% of patients with large B-cell lymphoma (LBCL) who are treated with axicabtagene ciloleucel (axi-cel) and who achieve a partial response (PR) or stable disease (SD) on the day 30 (D30) positron emission tomography (PET)-computed tomography (CT) scan progress; however, the factors that are predictive of progression are unknown. This a retrospective study of patients with LBCL who were treated with axi-cel at MD Anderson Cancer Center between January of 2018 and February of 2021. Among 50 patients with D30 PR/SD, 13 (26%) converted to a complete response (CR). Among 95 patients with a D30 CR, 72 (76%) remained in CR. On univariate analysis, the only day -5 characteristic associated with conversion from D30 PR/SD to subsequent CR was a higher platelet count (P = .05). The only D30 factor associated with conversion from D30 PR/SD to subsequent CR was a lower maximum standardized uptake volume (SUVmax; P < .001); all patients with D30 SUVmax ≥ 10 progressed. After a median follow-up of 12 months, no significant difference in median progression-free survival was observed between patients who converted from D30 PR/SD to subsequent CR and those who had been in CR since D30 (P = .19). Novel predictive and prognostic markers based on tissue biopsy and noninvasive diagnostic assays are needed to more effectively identify these patients and characterize the biology of their residual disease.
引用
- Al Zaki A, Feng L, Watson G, et al. Day 30 SUVmax predicts progression in patients with lymphoma achieving PR/SD after CAR T-cell therapy. Blood Adv. 2022. PMID: 35015825. doi:10.1182/bloodadvances.2021006715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。